Dewpoint Therapeutics Stock
HealthTechLooking to sell Dewpoint Therapeutics stock or options?
Dewpoint Therapeutics is developing a healthcare technology aimed at identifying new drugs for a wide range of diseases. By leveraging a proprietary experimental and AI-powered platform, the company enhances drug discovery. Dewpoint Therapeutics utilizes machine-learning-based image analysis tools to visualize condensates and offers an engine comprising a collection of engineered cell lines with trackable condensates to prevent detrimental protein sequestration. The company has active programs in oncology, neurodegenerative, cardiopulmonary, and metabolic diseases, and collaborates with leading academic and pharmaceutical partners globally. This enables healthcare providers to access new therapies that address unmet medical
Samsara BioCapital, Polaris Partners, ARCH Venture Partners, General Catalyst, Mirae Asset Capital, Leaps by Bayer, Maverick Ventures, Mubadala Capital, 3E Bioventures Capital, Caleb Appleton, Paratus Investment, EcoR1 Capital, SoftBank Investment Advisers, Alexandria Venture Investments, Timefolio Capital, Innovation Endeavors, 6 Dimensions Capital, Bellco Capital.